Azzad Asset Management Inc /Adv Gilead Sciences, Inc. Transaction History

Azzad Asset Management Inc /Adv

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 Apr 03, 2024	SELL	$72.84 - $88.8 $423,200 - $515,928	-5,810 Closed	0 $0
Q4 2017 Apr 03, 2024	SELL	$71.15 - $83.52 $1.19 Million - $1.4 Million	-16,737 Reduced 74.23%	5,810 $416 Million
Q3 2017 Apr 03, 2024	BUY	$72.11 - $85.47 $47,232 - $55,982	655 Added 2.99%	22,547 $1.83 Billion
Q2 2017 Apr 03, 2024	BUY	N/A	1,222 Added 5.91%	21,892 $1.55 Billion
Q1 2017 Apr 03, 2024	BUY	N/A	1,600 Added 8.39%	20,670 $1.4 Billion
Q4 2016 Apr 03, 2024	BUY	N/A	691 Added 3.76%	19,070 $1.37 Billion
Q3 2016 Apr 03, 2024	BUY	N/A	3,632 Added 24.63%	18,379 $1.45 Billion
Q2 2016 Apr 03, 2024	BUY	N/A	2,154 Added 17.1%	14,747 $1.23 Billion
Q1 2016 Apr 03, 2024	BUY	N/A	817 Added 6.94%	12,593 $1.16 Billion
Q4 2015 Apr 03, 2024	BUY	N/A	1,049 Added 9.78%	11,776 $1.19 Billion
Q3 2015 Apr 03, 2024	BUY	N/A	1,023 Added 10.54%	10,727 $1.05 Billion
Q2 2015 Apr 03, 2024	BUY	N/A	921 Added 10.49%	9,704 $1.14 Billion
Q1 2015 Apr 03, 2024	BUY	N/A	4,212 Added 92.15%	8,783 $862 Million
Q4 2014 Apr 03, 2024	BUY	N/A	251 Added 5.81%	4,571 $431 Million
Q3 2014 Apr 03, 2024	BUY	N/A	196 Added 4.75%	4,320 $460 Million
Q2 2014 Apr 03, 2024	BUY	N/A	26 Added 0.63%	4,124 $342 Million
Q1 2014 Apr 03, 2024	BUY	N/A	281 Added 7.36%	4,098 $290 Million
Q4 2013 Apr 03, 2024	BUY	N/A	322 Added 9.21%	3,817 $287 Million
Q2 2013 Apr 03, 2024	SELL	N/A	-2,847 Reduced 44.89%	3,495 $220 Million
Q1 2013 Apr 03, 2024	BUY	N/A	6,342 New	6,342 $310 Million
Q4 2012 Apr 08, 2024	SELL	N/A	-485 Reduced 13.46%	3,117 $229 Million
Q3 2012 Apr 08, 2024	BUY	N/A	3,602	3,602 $239 Million

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Azzad Asset Management Inc /Adv, based on Form 13F filings with the SEC.

Stay updated on Azzad Asset Management Inc /Adv with notifications on news.